Work

55P Impact of KRAS/TP53 and KEAP1/STK11 co-mutations on immune checkpoint inhibitor outcomes for metastatic NSCLC patients: Insights from real-world data

Year: 2026

Type: article

Abstract: Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy (ICI+CTx), are standard first-line treatments for metastatic non-small cell lung cancer (mNSCLC). While PD-L1 expression is currently the only biomarker used to guide the therapy choice, its predictive power is limited, and clinical outcome remains heterogeneous. We evaluated the impact of KRAS/TP53 and KEAP1/STK11 alterations on the clinical benefit of ICI/ICI+CTx therapy using data from the Baden-Wuerttemberg Cancer Registry (BWCR), Germany.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106362

Authors: D. Kokh, I. Surovtsova, W.E.E. Eberhardt, J. Judickiene, P. Morakis

Institutions: Ruhrlandklinik, Stiftung Universitätsmedizin Essen

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910